{
  "source": "PA-Med-Nec-Fabhalta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2324-4\nProgram Prior Authorization/Medical Necessity\nMedication Fabhalta® (iptacopan)\nP&T Approval Date 2/2024, 4/2024, 10/2024, 5/2025\nEffective Date 8/1/2025\nA. Background\nFabhalta (iptacopan) is a complement factor B inhibitor, indicated for the treatment of adults\nwith paroxysmal nocturnal hemoglobinuria (PNH); the reduction of proteinuria in adults with\nprimary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally\na urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g; and for the treatment of adults with\ncomplement 3 glomerulopathy (C3G), to reduce proteinuria.1\nB. Coverage Criteriaa:\nA. Paroxysmal nocturnal hemoglobinuria (PNH)\n1. Initial Authorization\na. Fabhalta will be approved based on all of the following criteria:\n(1) Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) as\nconfirmed by both of the following2,3,4,5:\n(a) Flow cytometry analysis confirming presence of PNH clones\n-AND-\n(b) Laboratory results, signs, and/or symptoms attributed to PNH (e.g.,\nabdominal pain, anemia, dyspnea, extreme fatigue, smooth muscle dystonia,\nunexplained/unusual thrombosis, hemolysis/hemoglobinuria, kidney\ndisease, pulmonary hypertension, etc.)\n-AND-\n(2) One of the following:\n(a) Patient will not be prescribed Fabhalta in combination with another\ncomplement inhibitor used for the treatment of PNH (e.g., Empaveli,\nPiaSky, eculizumab, Ultomiris)\n-OR-\n(b) Patient is currently receiving another complement inhibitor (e.g., Empaveli,\nPiaSky, eculizumab, Ultomiris) which will be discontinued and Fabhalta\n© 2025 UnitedHealthcare Services Inc.\n1\nwill be initiated in accordance with the United States Food and Drug\nAdministration approved labeling\n-AND-\n(3) Prescribed by, or in consultation with one of the following:\n(a) Hematologist\n(b) Oncologist\nAuthorization will be issued for 12 months",
    " States Food and Drug\nAdministration approved labeling\n-AND-\n(3) Prescribed by, or in consultation with one of the following:\n(a) Hematologist\n(b) Oncologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fabhalta will be approved based on all the following criteria:\n(1) Documentation of positive clinical response to Fabhalta therapy (e.g., increased\nor stabilization of hemoglobin levels, reduction in transfusions, improvement in\nhemolysis, decrease in LDH, increased reticulocyte count, etc.)\n-AND-\n(2) Patient is not receiving Fabhalta in combination with another complement\ninhibitor used for the treatment of PNH (e.g., Empaveli, PiaSky, eculizumab,\nUltomiris)\n-AND-\n(3) Prescribed by, or in consultation with one of the following:\n(a) Hematologist\n(b) Oncologist\nAuthorization will be issued for 12 months.\nB. Primary immunoglobulin A nephropathy (IgAN)\n1. Initial Authorization\na. Fabhalta will be approved based on all the following criteria:\n(1) Diagnosis of primary immunoglobulin A nephropathy (IgAN) confirmed by\nrenal biopsy\n-AND-\n(2) Patient is at risk of rapid disease progression [e.g., generally a urine protein-to-\ncreatinine ratio (UPCR) greater than or equal to 1.5 g/g, or by other criteria such\nas clinical risk scoring using the International IgAN Prediction Tool]\n© 2025 UnitedHealthcare Services Inc.\n2\n-AND-\n(3) Used to reduce proteinuria\n-AND-\n(4) Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2\n-AND-\n(5) One of the following:\n(a) Patient is on a stabilized dose and receiving concomitant therapy with one\nof the following:\ni. Maximally tolerated angiotensin converting enzyme (ACE) inhibitor\n(e.g., captopril, enalapril)\nii. Maximally tolerated angiotensin II receptor blocker (ARB) (e.g.,\ncandesartan, valsartan)\n-OR-\n(b) Patient has an allergy, contraindication, or intolerance to ACE inhibitors and\nARBs\n-AND-\n(6) One of the following:\n(a) Patient is on a stabilized dose and receiving concomitant therapy with a\nmaximally tolerat",
    "s an allergy, contraindication, or intolerance to ACE inhibitors and\nARBs\n-AND-\n(6) One of the following:\n(a) Patient is on a stabilized dose and receiving concomitant therapy with a\nmaximally tolerated sodium-glucose cotransporter-2 (SGLT2) inhibitor\n[e.g., Jardiance (empagliflozin)]\n-OR-\n(b) Patient has an allergy, contraindication, or intolerance to SGLT2 inhibitors\n-AND-\n(7) History of failure, contraindication or intolerance to a 30-day trial of a\nglucocorticoid (e.g., methylprednisolone, prednisone)\n-AND-\n(8) Prescribed by or in consultation with a nephrologist\nAuthorization will be issued for 12 months.\n© 2025 UnitedHealthcare Services Inc.\n3\n2. Reauthorization\n(1) Fabhalta will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Fabhalta therapy demonstrated\nby a reduction in proteinuria\nAuthorization will be issued for 12 months.\nC. Complement 3 glomerulopathy (C3G)\n1. Initial Authorization\na. Fabhalta will be approved based on all the following criteria:\n(1) Diagnosis of complement 3 glomerulopathy (C3G) confirmed by all of the\nfollowing:\n(a) Documentation of a kidney biopsy demonstrating characteristic findings of\nC3G\n-AND-\n(b) Glomerulonephritis has persisted ≥ 3 months in duration\n-AND-\n(c) One of the following:\ni. Serum complement 3 (C3) protein < 77 mg/dL (alternatively, less than\n0.85 x lower limit of the central laboratory normal range)\nii. Other complement abnormalities are present [e.g., soluble membrane\nattack complex (sC5b-9), serum factor H, serum factor B, factor I,\nmembrane cofactor protein (MCP, CD46), C3/C4/C5 nephritic factor\n(NeF)] which are suggestive of a C3 glomerulopathy\n-AND-\n(d) Presence of monoclonal gammopathy of undetermined significance\n(MGUS) has been excluded by measurement of serum free light chains or\nother investigative means based on standards of care\n-AND-\n(2) Disease is considered to be moderate to severe based on proteinuria ≥ 1.5 g/day\nand/or abnormal kidney function\n-AND-\n©",
    "e light chains or\nother investigative means based on standards of care\n-AND-\n(2) Disease is considered to be moderate to severe based on proteinuria ≥ 1.5 g/day\nand/or abnormal kidney function\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n4\n(3) Used to reduce proteinuria\n-AND-\n(4) History of failure, contraindication or intolerance to a glucocorticoid (e.g.,\nmethylprednisolone, prednisone)\n-AND-\n(5) One of the following:\n(a) Patient is on a stabilized dose and receiving concomitant therapy with one\nof the following:\ni. Maximally tolerated angiotensin converting enzyme (ACE) inhibitor\n(e.g., captopril, enalapril)\nii. Maximally tolerated angiotensin II receptor blocker (ARB) (e.g.,\ncandesartan, valsartan)\n-OR-\n(b) Patient has an allergy, contraindication, or intolerance to ACE inhibitors and\nARBs\n-AND-\n(6) Patient has not undergone a solid-organ or cell transplant, including kidney\ntransplant\n-AND-\n(7) Prescribed by or in consultation with a nephrologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Fabhalta will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Fabhalta therapy demonstrated\nby a reduction in proteinuria\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2025 UnitedHealthcare Services Inc.\n5\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place\n4. References:\n1. Fabhalta [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation;\nMarch 2025.\n2. Parker C, Omine M, Richards S, et ",
    "ic class.\n• Supply limits may be in place\n4. References:\n1. Fabhalta [package insert]. East Hanover, New Jersey: Novartis Pharmaceuticals Corporation;\nMarch 2025.\n2. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal\nhemoglobinuria. Blood. 2005 Dec 1; 106(12): 3699–3709.\n3. Devalet B, Mullier F, Chatelain B, et al. Pathophysiology, diagnosis, and treatment of paroxysmal\nnocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep;95(3):190-8.\n4. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity detection\nand monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B\nClin Cytom. 2012 Jul;82(4):195-208.\n5. Röth A, Maciejewski J, Nishimura JI, et al. Screening and diagnostic clinical algorithm for\nparoxysmal nocturnal hemoglobinuria: Expert consensus. Eur J Haematol. 2018 Jul;101(1):3-11.\n6. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group.\nKDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney\nInt. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021\n7. Kopel, T. C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis. In: UpToDate,\nLam, A (Ed), UpToDate, Waltham, MA, 2025.\nProgram Prior Authorization/Medical Necessity - Fabhalta® (iptacopan)\nChange Control\n2/2024 New program.\n4/2024 Simplified criteria language for converting to new complement inhibitor\ntherapy.\n10/2024 Updated background and included coverage criteria for primary\nimmunoglobulin A nephropathy (IgAN). Updated list of examples for\ncombination use requirement for PNH. Updated references.\n5/2025 Added new indication and criteria for C3 glomerulopathy (C3G).\nReplaced Soliris with eculizumab in list of examples of complement\ninhibitors. Updated background and references.\n© 2025 UnitedHealthcare Services Inc.\n6"
  ]
}